Legalizing psychedelics is a hot topic in seven U.S. states as lawmakers aim to follow in the footsteps of Oregon and Colorado. From state-regulated psychedelic therapy programs to the legalization of Schedule I substances, the range of legislation being introduced is broad.
One notable bill is the Compassionate Use and Research of Entheogens (CURE) Act in Illinois. The act would establish a state-regulated program for psychedelic-assisted therapy for adults over 18. Licensed facilitators would administer the treatment at designated service centers, and criminal penalties for psilocybin possession would be removed.
Impact Of The New Entheogens Bill On The Legalization Process
However, the process may be slowed down, as the bill was introduced by the legislature and contains more details, thus involving different interest groups. According to cannabis and psychedelics lawyer Joshua Kappel, the act’s definition of “compassionate use” of natural entheogens does not necessarily mean it is a non-medical model. The critical difference is that no diagnosis is required. This allows for people seeking psychedelics for wellness purposes, such as micro-dosing to break an alcohol dependency, or veterans seeking therapy outside federal law. It is worth noting that research shows that alcohol use disorder is lower in states that have legalized cannabis.
Across the United States, various states are pushing for the legalization of psilocybin and other psychedelics for therapeutic and medicinal purposes. Virginia’s HB 1513 would legalize psilocybin possession with a health professional prescription for the treatment of refractory depression, PTSD, and end-of-life anxiety, while SB 932 requests state-level reclassification of psilocybin from Schedule I to Schedule III.
Washington’s SB 5263, the Psilocybin Services Wellness and Opportunity Act, would create legal psilocybin services for state citizens 21 and older to improve physical, mental, and social well-being and to treat behavioral health disorders. New York’s recently filed bill would create a pilot program of psilocybin- and MDMA-assisted therapy for qualifying New Yorkers. At the same time, Connecticut’s HB 5102 requests legal psilocybin for therapeutic or medicinal purposes.
New Hampshire’s bill would legalize the possession and use of psychedelics, including psilocybin, for adults over 21. Meanwhile, Arizona’s bipartisan Reps have filed a bill promoting psilocybin research with grants of up to $30 million over three years for Phase 1, 2, or 3 clinical trials. With support from both sides of the aisle, the movement to re-evaluate the regulation of psychedelics is gaining momentum.
The Push For Legalization Of Psilocybin: Exploring Its Therapeutic And Societal Impacts
Psilocybin, a natural psychedelic found in mushrooms, is gaining more attention as several states in the U.S. are pushing for the legalization of its therapeutic use. The decriminalization and rescheduling of psychedelics have the potential to significantly impact mental health treatment, especially in conditions such as depression and PTSD, where current treatments have not been effective for many patients. The legalization of psilocybin services, as seen in the bills introduced in Virginia, Washington, and New York, would not only allow for more widespread access to these treatments but also protect healthcare professionals and providers from prosecution.
In addition to its potential therapeutic benefits, the legalization of psilocybin services can also help reduce the stigma surrounding mental health and substance use disorders. The support for these bills from both sides of the aisle in the legislative process shows a shift in how psychedelics are viewed, from dangerous drugs to potentially beneficial medicines. Furthermore, the promotion of industry participation from low-income communities, military veterans, and indigenous people, as seen in Washington’s SB 5263, highlights the potential for these treatments to reach a wider range of individuals who may benefit from them. It may also be possible to treat extreme grief.
The legalization of psilocybin services and the granting of research grants, as seen in Arizona, would also pave the way for further scientific studies to be conducted. This would deepen our understanding of the effects of psychedelics on the brain and lead to the development of new and more effective treatments for mental health disorders. The granting of research grants specifically for whole mushroom psilocybin studies would allow for the exploration of the full range of its effects rather than just its isolated compounds, which could lead to a more comprehensive understanding of the potential benefits and risks associated with its use.
Enjoyed that first hit? Come chill with us every week at the Friday Sesh for a freshly packed bowl of the week’s best cannabis news!
